Novartis to Acquire Crinetics Pharmaceuticals for $2.7B

Ticker: CRNX · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1658247

Crinetics Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCrinetics Pharmaceuticals, Inc. (CRNX)
Form Type8-K
Filed DateMar 12, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: acquisition, merger, healthcare, biotech

TL;DR

Novartis is buying Crinetics for $2.7B ($11/share) to boost its cancer drug pipeline.

AI Summary

Crinetics Pharmaceuticals, Inc. announced on March 12, 2024, that it has entered into a definitive agreement to be acquired by Novartis AG. The transaction is valued at approximately $2.7 billion, with Novartis acquiring all outstanding shares of Crinetics for $11.00 per share in cash. This acquisition aims to strengthen Novartis's radioligand therapy portfolio.

Why It Matters

This acquisition significantly expands Novartis's presence in the radioligand therapy market, potentially leading to new treatment options for cancer patients.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction from closing.

Key Numbers

  • $2.7B — Acquisition Value (Total amount Novartis is paying to acquire Crinetics.)
  • $11.00 — Price Per Share (Cash amount shareholders will receive for each share of Crinetics.)

Key Players & Entities

  • Crinetics Pharmaceuticals, Inc. (company) — Company filing the report and being acquired
  • Novartis AG (company) — Acquiring company
  • $2.7 billion (dollar_amount) — Total value of the acquisition
  • $11.00 (dollar_amount) — Price per share in the acquisition
  • March 12, 2024 (date) — Date of the report and announcement

FAQ

What is the primary strategic rationale for Novartis acquiring Crinetics?

Novartis is acquiring Crinetics to strengthen its radioligand therapy portfolio, a key area of focus for the company.

What is the total value of the transaction?

The definitive agreement values the transaction at approximately $2.7 billion.

What price will Crinetics shareholders receive?

Crinetics shareholders will receive $11.00 in cash for each outstanding share of Crinetics common stock.

When was this acquisition announced?

The announcement was made on March 12, 2024, as reported in this Form 8-K.

Are there any conditions to closing the acquisition?

Yes, the transaction is subject to customary closing conditions, including regulatory approvals.

Filing Stats: 1,094 words · 4 min read · ~4 pages · Grade level 13.2 · Accepted 2024-03-12 16:25:02

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements, including statements regarding the plans and timelines for the clinical development of paltusotine and CRN04894, including the therapeutic potential and clinical benefits or safety profile thereof; plans and timing for sharing the full results of the Phase 2 study of paltusotine in CS with the FDA to align on and design a Phase 3 program; plans and timing to further develop paltusotine in carcinoid syndrome or to conduct Phase 3 studies of paltusotine in carcinoid syndrome; the potential benefits of CRN04894 in patients with Congenital Adrenal Hyperplasia or Cushing's disease and the expected plans and timing for data from ongoing clinical studies; the potential for any of our ongoing clinical studies to show safety or efficacy; the potential for our discovery program for endocrine diseases including hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity to progress to drug candidates and show safety or efficacy; and our plans to identify and create new drug candidates for additional diseases. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, topline results that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, the possibility of unfavorable new clinical data and further analyses of existing clinical data, and the FDA and other regulatory authorities may not agree with our interpretation of such results; and the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date:March 12, 2024 By: /s/ R. Scott Struthers, Ph. D. R. Scott Struthers, Ph. D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.